Communiqués Curasight A/S

Actions

Cours en clôture NORDIC GROWTH MARKET Autres places de cotation 00:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
12,5 ^DKK	-10,71 %		-9,75 %	-29,58 %

12/06	Curasight A/S annonce le recrutement du premier patient dans l'étude de phase 2 avec uTRACE[®] dans le cancer de la prostate	CI
23/05	Curasight A/S publie ses résultats pour le premier trimestre clos le 31 mars 2024	CI

BioStock: Curasight CEO comments on capital raise and milestone	25/06	AQ
Curasight: Curasight to present at HC Andersen Capital	24/06	PU
Curasight to present at HC Andersen Capital	22/06	AQ
Curasight: Notice of Extraordinary General Meeting	17/06	PU
Curasight: Curasight A/S resolves on directed issues and a loan facility	14/06	PU
Curasight A/S resolves on directed issues and a loan facility	14/06	AQ
Curasight: Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer	12/06	PU
Curasight Announces Enrollment of First Patient in Phase 2 trial with uTRACE[®] in Prostate Cancer	12/06	AQ
BioStock: Curasight committed to progressing pipeline	04/06	AQ
Curasight Q1 - Moving forward	27/05	AQ
Interim report Q1 2024	23/05	AQ
BioStock: Curasight gets green light from EMA in phase II prostate cancer trial	22/04	AQ
Curasight announces approval of clinical trial application (CTA) for phase 2 trial with uTRACE[®] in prostate cancer patients	16/04	AQ
Curasight announces change in the Board of Directors	12/04	AQ
BioStock: Curasight cancels rights issue and evaluates alternative financing	13/03	AQ
Curasight not to proceed with rights issue; evaluating alternative financing opportunities	11/03	AQ
Notice of Annual General Meeting 2024	06/03	AQ
The subscription period in Curasight's rights issue begins today	23/02	AQ
Curasight publishes information memorandum in connection with forthcoming rights issue	22/02	AQ
Annual Report for the fiscal year 2023	22/02	AQ

Aucun résultat pour cette recherche